NEW YORK, March 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with ...
TG Therapeutics outlines $825M–$850M BRIUMVI 2026 guidance while accelerating subcutaneous program
The company reaffirmed 2026 full year U.S. BRIUMVI net revenue guidance of $825 million to $850 million and total global revenue at $875 million to $900 million. Waldman indicated, “Turning to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results